Sarepta Therapeutics

SRPT · Nasdaq · United States

Share price · SRPT

$14.53-3.49 (-19.37%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.9M (0.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when SRPT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 9 Sep 2026+5.2%

    Nothing announced by SRPT that day or the session before.

  2. 2 Sep 2026+8.8%

    Nothing announced by SRPT that day or the session before.

  3. 27 Aug 2026+10.9%

    Nothing announced by SRPT that day or the session before.

  4. 11 Aug 2026+6.1%

    Nothing announced by SRPT that day or the session before.

  5. 3 Aug 2026+6.9%

    Nothing announced by SRPT that day or the session before.

  6. 21 Jul 2026-3.7%

    Nothing announced by SRPT that day or the session before.

  7. 30 Jun 2026+5.6%

    Nothing announced by SRPT that day or the session before.

  8. 25 Jun 2026-4.0%

    Nothing announced by SRPT that day or the session before.

  9. 24 Jun 2026-3.3%

    Nothing announced by SRPT that day or the session before.

  10. 25 Mar 2026+35.0%

    Nothing announced by SRPT that day or the session before.

Share of unusual movement by asset

For each asset, the share of SRPT's own-move activity since 13 Oct 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
SRP-1001
events and moves
1shown from 8 days
SRP-1003
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—22%
Other company news (earnings, financing, releases naming no asset)—2%
Sessions with no dated event—76%

Assets

(3 total)
3Total Assets
0Approved
0Phase 3 / Filed
3Phase 1–2 / Early
3Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 1/2
DUX4RNA / oligonucleotide
Facioscapulohumeral Muscular Dystrophy
Phase 1/2
DMPK (dystrophia myotonica protein kinase)RNA / oligonucleotide
Myotonic Dystrophy Type 1
Phase 1
ATXN2 (ataxin-2)RNA / oligonucleotide
Spinocerebellar Ataxia
Spinocerebellar Ataxia Type 2

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
SRP-1003Phase 1/2Myotonic Dystrophy 1
Est. primary completion 2026-12-31 · NCT06138743 · CT.gov ↗
What to watch
2028 (1)
December 2028 (1)
SRP-1001Phase 1/2Muscular Dystrophy, Facioscapulohumeral
Est. primary completion 2028-12-31 · NCT06131983 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

25 March 2026Topline resultSRP-1001First-in-human SRP-1001 data: muscle delivery and creatine kinase reduction

Financial reports

Quarterly & interim (17)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$381M$83M$473M+ $406M short-term inv.$28M$60M operating cash flowreport ↗
View 16 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$401M$91M$571M+ $217M short-term inv.$4.9M$197M operating cash flowreport ↗
2026-Q1$731M$154M$464M+ $189M short-term inv.—-$203M operating cash flowreport ↗
2025-Q4$443M—$801M+ $138M short-term inv.$412M$131M operating cash flowreport ↗
2025-Q3$399M$219M$613M+ $238M short-term inv.$180M-$15M operating cash flowreport ↗
2025-Q2$611M$204M$511M+ $290M short-term inv.—$261M operating cash flowreport ↗
2025-Q1$745M$773M$241M+ $282M short-term inv.$448M-$583M operating cash flowreport ↗
2024-Q4$658M—$1.1B+ $252M short-term inv.—$92M operating cash flowreport ↗
2024-Q3$467M$224M$198M+ $1.0B short-term inv.—-$71M operating cash flowreport ↗
2024-Q2$363M$180M$384M+ $1.1B short-term inv.—$15M operating cash flowreport ↗
2024-Q1$413M$200M$427M+ $963M short-term inv.—-$242M operating cash flowreport ↗
2023-Q3$332M$194M$542M+ $1.2B short-term inv.$41M-$115M operating cash flowreport ↗
2023-Q2$261M$242M$852M+ $1.0B short-term inv.$24M-$122M operating cash flowreport ↗
2023-Q1$254M$246M$872M+ $1.0B short-term inv.$517M-$209M operating cash flowreport ↗
2022-Q3$230M$217M$1.0B+ $1.0B short-term inv.$258M-$65M operating cash flowreport ↗
2022-Q2$233M$252M$869M+ $1.1B short-term inv.$231M-$67M operating cash flowreport ↗
2022-Q1$211M$194M$1.2B+ $780M short-term inv.$105M-$101M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$2.2B$1.5B$801M+ $138M short-term inv.$178M-$205M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$1.9B$805M$1.1B+ $252M short-term inv.—-$206M operating cash flowreport ↗
2023-FY$1.2B$877M$428M+ $1.2B short-term inv.$134M-$501M operating cash flowreport ↗
2022-FY$933M$877M$967M+ $1.0B short-term inv.$176M-$325M operating cash flowreport ↗
2021-FY$702M$771M$2.1B+ $0 short-term inv.$105M-$443M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 2 sales ($417K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-04Rodino-Klapac Louise · President, R&D and Tech OpsTax withholding21,423$22.22$476KForm 4
2026-09-04Rothfuss Cristin · EVP, General CounselTax withholding22,025$22.22$489KForm 4
2026-09-04Estepan Ian Michael · Chief Operating OfficerTax withholding24,799$22.22$551KForm 4
2026-09-04Wong Ryan Ho-Yan · Chief Financial OfficerTax withholding13,272$22.22$295KForm 4
2026-07-28SEVERINO MICHAEL · director, Chief Executive OfficerAward / grant756,104——Form 4
2026-07-28SEVERINO MICHAEL · director, Chief Executive OfficerAward / grant (derivative)2,224,342——Form 4
2026-06-04Barry Richard · directorAward / grant16,875——Form 4
2026-06-04Chambers Michael Andrew · directorAward / grant16,875——Form 4